Cytotoxic chemotherapy for advanced, non-resectable colorectal cancer

European Journal of Surgical Oncology

Volumn 33, Issue SUPPL. 2, 2007, Pages

  Valle, J W ^a,b   Board, R E ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 FU; capecitabine; Cytotoxic chemotherapy; Irinotecan; Non resectable colorectal cancer; Oxaliplatin; UFT

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ABDOMINAL CRAMP; ALOPECIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CEREBELLAR ATAXIA; COLORECTAL CANCER; CYTOTOXIC CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG INHIBITION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSESTHESIA; EPIPHORA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; NAUSEA AND VOMITING; NEUROPATHY; NON RESECTABLE COLORECTAL CANCER; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; SWEATING; TREATMENT INDICATION;

EID: 36749097483     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.10.010     Document Type: Review

References (60)

1. Toms J. CancerStats monograph 2004 (2004), Cancer Research UK, London
2. Simmonds P.C., and Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321 (2000) 531-535
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10 (1992) 896-903
4. Thirion P., Michiels S., Pignon J.P., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22 (2004) 3766-3775
5. Poon M.A., O'Connell M.J., Moertel C.G., et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7 (1989) 1407-1418
6. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15 (1997) 808-815
7. Cheeseman S.L., Joel S.P., Chester J.D., et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87 (2002) 393-399
8. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16 (1998) 301-308
9. Borner M.M., Schoffski P., de Wit R., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 (2002) 349-358
10. Liu G., Franssen E., Fitch M.I., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 (1997) 110-115
11. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 (1998) 1274-1281
12. Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45 (2000) 291-297
13. Van Cutsem E., Hoff P.M., Harper P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90 (2004) 1190-1197
14. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 (2002) 566-575
15. Haller D., Cassidy J., Clarke S., et al. Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol (2006) 2006 ASCO Annual Meeting Proceedings Part I: 24: 3514
16. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 (2004) 2084-2091
17. Borner M.M., Dietrich D., Stupp R., et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20 (2002) 1759-1766
18. Rea D.W., Nortier J.W., Ten Bokkel Huinink W.W., et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16 (2005) 1123-1132
19. Cartwright T., Lopez T., Vukelja S.J., et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5 (2005) 50-56
20. Carmichael J., Popiela T., Radstone D., et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3617-3627
21. Douillard J.Y., Hoff P.M., Skillings J.R., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3605-3616
22. Douillard J.Y., Bennouna J., Artru P., et al. UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients with non-resectable metastatic colorectal cancer (MCRC): results of two multicentric phase II trials. J Clin Oncol 23 Suppl. (2004) (Abstract 3545)
23. Mendez M., Alfonso P.G., Pujol E., et al. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs 23 (2005) 243-251
24. Delord J.P., Bennouna J., Artru P., et al. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer 97 (2007) 297-301
25. Rosati G., Cordio S., Tucci A., et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69 (2005) 122-129
26. Feliu J., Vicent J.M., Garcia-Giron C., et al. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 91 (2004) 1758-1762
27. Bennouna J., Perrier H., Paillot B., et al. A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 94 (2006) 69-73
28. Hoff P.M., and Pazdur R. UFT plus oral leucovorin: a new oral treatment for colorectal cancer. Oncologist 3 (1998) 155-164
29. Morton C.L., Wadkins R.M., Danks M.K., et al. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59 (1999) 1458-1463
30. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
31. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (1998) 1407-1412
32. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [see comments]. N Engl J Med 343 (2000) 905-914
33. Kohne C.H., van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23 (2005) 4856-4865
34. Rothenberg M.L., Meropol N.J., Poplin E.A., et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19 (2001) 3801-3807
35. Culy C.R., Clemett D., and Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60 (2000) 895-924
36. Andre T., Bensmaine M.A., Louvet C., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17 (1999) 3560-3568
37. Brienza S., Bensmaine M.A., Soulie P., et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 10 (1999) 1311-1316
38. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33 (1997) 214-219
39. Janinis J., Papakostas P., Samelis G., et al. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 11 (2000) 163-167
40. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
41. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
42. Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21 (2002) 129a (Abstract 512)
43. Cassidy J., Clarke S., Diaz-Rubio E., et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 17 (2006) LBA3
44. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
45. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005) 4866-4875
46. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
47. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
48. Folprecht G., Rougier P., Saltz L.B., et al. Irinotecan in first-line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan. J Clin Oncol (2006) 2006 ASCO Annual Meeting Proceedings Part I: 24: 3578
49. Figer A., Perez N., Carola E., et al. 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. J Clin Oncol 23 (2004) (Abstract 3571)
50. Ackland S.P., Jones M., Tu D., et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 93 (2005) 1236-1243
51. Lokich J.J., Ahlgren J.D., Cantrell J., et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer 67 (1991) 14-19
52. Maughan T., James R.D., Kerr D., et al. Preliminary results of a multicentre randomised trial comparing 3 chemotheraoy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 18 (1999) 262a (Abstract)
53. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24 (2006) 394-400
54. Maindrault-Goebel F., Lledo G., Chibaudel B., et al. Final results of OPTIMOX2, a large randomised phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol (2007) 2007 ASCO Annual Meeting Proceedings Part I: 25 (Abstract 4013)
55. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
56. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
57. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
58. Grothey A., and Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23 (2005) 9441-9442
59. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
60. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 (2005) 6212-6217